Business Wire

• Pantheon and iCapital will leverage iCapital’s innovative technology and structuring capabilities to bring Pantheon’s high conviction private equity investments to a wider range of global investors
• Partnership also includes solutions targeting markets with growing demand across Europe, the Middle East, Latin America and Asia

LONDON--(BUSINESS WIRE)-- Pantheon, a leading specialist global private markets investor, and iCapital1, the global fintech... (continue reading...)

Hall 1, 4F, Booth #N0602

TAIPEI, Taiwan--(BUSINESS WIRE)-- Newegg Commerce, Inc. (NASDAQ: NEGG), a leading global e-commerce company specializing in computers and consumer electronics, today announced its largest-ever presence at the premier APAC computer convention, the 2024 Taipei International Computer Show (COMPUTEX 2024), June 4-7, in Taipei, Taiwan.

This press release features multimedia. View the full release here: ... (continue reading...)

FourKites is the first real-time visibility platform participating in the SSC

AMSTERDAM--(BUSINESS WIRE)-- Leading real-time supply chain visibility provider FourKites® today announced its role as a Collaborator in the Scheduling Standards Consortium (SSC) as the first real-time visibility platform participating. FourKites joins organisations involved with the SSC — including Arrive Logistics, BlueYonder, Coyote Logistics, DHL, e2open, Echo, J.B. Hunt... (continue reading...)

Informatica plans office opening in Saudi to solidify AI-powered presence in region

News follows Informatica’s announcement of first ever Intelligent Data Management Cloud™ (IDMC) platform in Kingdom

RIYADH, Saudi Arabia--(BUSINESS WIRE)-- Informatica (NYSE: INFA), an enterprise cloud data management leader, today opened its doors to the first major data innovation summit in the Kingdom, which is set to outline a roadmap for how Saudi Arabia can accelerate... (continue reading...)

JJP Biologics has received a positive conclusion on the Clinical Trial Application assessment for a Phase I Study of a potential first-in-class anti-CD89 antagonist, JJP-1212 monoclonal antibody for the treatment of various IgA-mediated autoimmune- and fibrotic diseases.

WARSAW, Poland--(BUSINESS WIRE)-- JJP Biologics, a private biopharmaceutical company developing innovative antibody-based therapies, announces a positive decision, issued by the European... (continue reading...)